Rocket Pharmaceuticals, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
At close
$4.90
−$0.11 (−2.22%) Close
Prev closePrevC$5.01
OpenOpen$4.94
Day highHigh$4.94
Day lowLow$4.89
VolumeVol5,214
Avg volAvgVol2,389,262
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$542.19M
P/E ratio
-2.44
EPS
-2.01
Sector
Healthcare
AI report sections
MIXED
RCKT
Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals shows short- to medium-term price stabilization with positive 1–6 month returns and multiple bullish technical signals after a steep 12‑month drawdown. At the same time, the company remains deeply loss-making with substantial negative free cash flow and relies on external financing to support its gene therapy pipeline. Elevated short interest and a cluster of negative legal and clinical headlines indicate ongoing perception and headline risk around the RP‑A501 program.
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Law firm investigating Rocket Pharmaceuticals for potential securities fraud related to undisclosed clinical trial protocol changes and serious adverse events in RP-A501 study, which led to a 37% stock price drop.
Company allegedly concealed material adverse facts about clinical trial safety, failed to disclose protocol amendments, and experienced significant stock price decline after FDA placed clinical hold on study due to patient death
NegativeGlobeNewswire Inc.• Law Offices Of Howard G. Smith
DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Law firm alerts investors about potential securities fraud class action lawsuits for four companies, alleging misleading statements and undisclosed risks during specific class periods in 2024-2025.
Accused of hiding serious study risks, including participant deaths and undisclosed protocol amendments
NegativeGlobeNewswire Inc.• Rosen Law Firm
RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT
Rosen Law Firm alerts Rocket Pharmaceuticals investors about a securities class action lawsuit alleging false statements regarding the effectiveness and safety of drug candidate RP-A501, with an important deadline on August 11, 2025.
RCKTRCKTWsecurities lawsuitclass actionpharmaceuticalclinical trialinvestor rights
Sentiment note
The lawsuit alleges the company made false and misleading statements about its drug candidate RP-A501's effectiveness, safety, and clinical prospects, suggesting potential misconduct and potential financial harm to investors
NegativeBenzinga• Business Wire
Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Law Offices of Frank R. Cruz alerts investors about an upcoming August 11, 2025 deadline to participate in a securities fraud class action lawsuit against Rocket Pharmaceuticals following an FDA clinical hold on a Danon disease treatment trial after a patient's death.
Stock price dropped 62.8% after FDA placed a clinical hold on their Phase 2 trial due to a patient's death, and allegations of misleading investors about serious adverse events and protocol changes
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Rocket Pharmaceuticals faces a class action lawsuit alleging misleading statements about its Phase 2 clinical trial for RP-A501, with claims of concealing serious adverse events including patient death, which led to an FDA clinical hold and stock price decline.
The lawsuit alleges the company concealed critical safety information about its clinical trial, resulting in an FDA clinical hold, potential patient deaths, and a stock price drop, indicating significant legal and reputational risks
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Rocket Pharmaceuticals faces a class action lawsuit after disclosing an FDA clinical hold on its Danon disease treatment trial following a patient's death, causing significant stock price decline.
Stock price dropped 62.8% after revealing serious adverse event in clinical trial, potential failure to disclose critical protocol changes, and FDA placing clinical hold on trial
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
A class action lawsuit has been filed against Rocket Pharmaceuticals after the FDA placed a clinical hold on its RP-A501 Phase 2 pivotal study following a patient's death, causing the stock price to drop 37% in one trading day.
Stock price dropped 37% after FDA clinical hold due to patient death, potential securities law violations, and alleged concealment of material adverse facts about clinical trial protocol
NegativeGlobeNewswire Inc.• Pomerantz Llp
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
Pomerantz Law Firm filed a class action lawsuit against Rocket Pharmaceuticals after a patient death in a Phase 2 gene therapy trial, causing the stock to drop 62.84%.
Stock price dropped significantly after a patient death in a clinical trial, FDA placed a clinical hold, and a lawsuit was filed alleging potential securities fraud
NegativeGlobeNewswire Inc.• Hagens Berman
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman
Rocket Pharmaceuticals faces a securities class action lawsuit after the FDA placed a clinical hold on its Phase 2 trial for RP-A501, a gene therapy for Danon disease, causing its stock to drop over 60% on May 27, 2025.
Stock price dropped 62% after FDA clinical hold, allegations of misleading investors about trial protocol changes and potential serious adverse events, and ongoing class action lawsuit
NegativeGlobeNewswire Inc.• Rosen Law Firm
מועד אחרון חשוב לתביעה נגד RCKT: רוזן, משרד ארצי מוביל, מעודד משקיעים ב- Rocket Pharmaceuticals, Inc עם הפסדים של יותר מ-100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב של 11 באוגוסט בתביעה ייצוגית בניירות ערך - RCKT
Rosen Law Firm alerts Rocket Pharmaceuticals investors about a securities class action lawsuit alleging false statements about clinical trial effectiveness and safety of drug RP-A501, with an important filing deadline on August 11, 2025.
RCKTRCKTWsecurities lawsuitpharmaceuticalclinical trialsinvestor rights
Sentiment note
The lawsuit alleges the company made misleading statements about drug effectiveness, safety risks, and clinical trial protocols, suggesting potential misconduct that could negatively impact investor confidence
NegativeGlobeNewswire Inc.• Rosen Law Firm
RCKT IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT
Rosen Law Firm is investigating potential securities claims for Rocket Pharmaceuticals investors who purchased securities between September 17, 2024 and May 26, 2025, alleging false statements about drug effectiveness and safety.
RCKTRCKTWsecurities lawsuitclass actionpharmaceuticalclinical trialsinvestor rights
Sentiment note
Lawsuit alleges company made false and misleading statements about drug RP-A501's effectiveness, safety, and clinical prospects, suggesting potential misconduct and potential financial harm to investors
NegativeGlobeNewswire Inc.• Portnoy Law Firm
Rocket Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 11, 2025 Deadline to file Lead Plaintiff Motion.
Rocket Pharmaceuticals faces a class action lawsuit alleging misleading statements about its Phase 2 trial for Danon disease treatment, with claims of undisclosed serious adverse events and protocol changes leading to an FDA clinical hold.
The company is accused of providing false and misleading information about its clinical trial, failing to disclose critical protocol changes, and experiencing an FDA clinical hold following a patient death, which likely caused significant stock price decline
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
